Institute of Chinese Medicine, State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China.
Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
Int J Mol Sci. 2024 Aug 8;25(16):8655. doi: 10.3390/ijms25168655.
Allergic rhinitis (AR) is a series of allergic reactions to allergens in the nasal mucosa and is one of the most common allergic diseases that affect both children and adults. Shi-Bi-Lin (SBL) is the modified formula of Cang Er Zi San (CEZS), a traditional Chinese herbal formula used for treating AR. Our study aims to elucidate the anti-inflammatory effects and mechanisms of SBL in house dust mite-induced AR by regulating gut microflora metabolism. In vivo studies showed that nasal allergies and the infiltration of inflammatory cells in the nasal epithelium were significantly suppressed by SBL. Moreover, SBL restored the impaired nasal epithelial barrier function with an increased tight junction protein expression and reduced the endothelial nitric oxide synthase (eNOS). Interestingly, SBL significantly reconstituted the abundance and composition of gut microbiota in AR mice; it increased the relative abundance of potentially beneficial genera and decreased the relative abundance of harmful genera. SBL also restored immune-related metabolisms, which were significantly increased and correlated with suppressing inflammatory cytokines. Furthermore, a network analysis and molecular docking indicated IL-6 was a possible target drug candidate for the SBL treatment. SBL dramatically reduced the IL-6 level in the nasal lavage fluid (NALF), suppressing the IL-6 downstream Erk1/2 and AKT/PI3K signaling pathways. In conclusion, our study integrates 16S rRNA sequencing, microflora metabolism, and network pharmacology to explain the immune mechanism of SBL in alleviating HDM-induced allergic rhinitis.
变应性鼻炎(AR)是一系列鼻黏膜对变应原的过敏反应,是影响儿童和成人的最常见过敏性疾病之一。史碧林(SBL)是苍耳子散(CEZS)的改良配方,用于治疗 AR。我们的研究旨在通过调节肠道微生物群代谢来阐明 SBL 对屋尘螨诱导的 AR 的抗炎作用和机制。体内研究表明,SBL 显著抑制鼻过敏和鼻上皮炎症细胞浸润。此外,SBL 恢复了受损的鼻上皮屏障功能,增加了紧密连接蛋白的表达,降低了内皮型一氧化氮合酶(eNOS)。有趣的是,SBL 显著重建了 AR 小鼠的肠道微生物群的丰度和组成;它增加了潜在有益属的相对丰度,降低了有害属的相对丰度。SBL 还恢复了免疫相关代谢物,这些代谢物显著增加,并与抑制炎症细胞因子相关。此外,网络分析和分子对接表明,IL-6 可能是 SBL 治疗的候选药物靶点。SBL 显著降低了鼻灌洗液(NALF)中的 IL-6 水平,抑制了 IL-6 下游的 Erk1/2 和 AKT/PI3K 信号通路。总之,我们的研究整合了 16S rRNA 测序、微生物群代谢和网络药理学,以解释 SBL 缓解 HDM 诱导的变应性鼻炎的免疫机制。